Ocular Therapeutix will use May’s ophthalmology and investor meetings to showcase its retina ambitions, headlined by the first Phase...

Idorsia opened 2026 with a 74% year-over-year jump in QUVIVIQ net sales to CHF 44 million, fresh Phase 2...

Biomea Fusion reported 52-week data from its Phase 2, open-label COVALENT-112 trial in type 1 diabetes showing that a...

Dark Horse Consulting Group and Porton Advanced have signed a memorandum of understanding to create an integrated pathway for...

Codexis will report first-quarter 2026 results on May 7 after market close, with a management call to follow. For...

Theialife has appointed Thomas Ruggia as President and CEO as it readies Phase 3 development for ND10, an oral...

Agomab Therapeutics has extended its cash runway into the first half of 2029 after raising $208 million in gross...

Trevi Therapeutics is lining up a concentrated May roadshow around Haduvio, its oral extended-release nalbuphine for chronic cough, with...

Clinuvel has secured final scientific advice from the European Medicines Agency on its pivotal Phase III CUV107 trial evaluating...

WHO has prequalified Coartem (artemether-lumefantrine) Baby, a new formulation designed for newborns and young infants weighing 2 to 5...